Proposed Collection; 60-Day Comment Request; State and Community Tobacco Control Research Initiative Evaluation (NCI), 32742-32743 [2014-13271]
Download as PDF
32742
Federal Register / Vol. 79, No. 109 / Friday, June 6, 2014 / Notices
under the Agreement) and Certifications
of Exemption.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
DESCRIPTION OF RECORDS TO BE USED IN THE
MATCHING PROGRAM:
National Institutes of Health
The matching program is conducted
with data maintained by CMS in the
Health Insurance Exchanges System
(HIX), CMS System No. 09–70–0560, as
amended, published at 78 FR 8538 (Feb.
6, 2013), 78 FR 32256 (May 29, 2013)
and 78 FR 63211 (October 23, 2013).
The matching program is also
conducted with data maintained by SSA
in the following SORs:
• Master Files of SSN Holders and
SSN Applications, SSA/OEEAS, 60–
0058, 75 FR 82121 (December 29, 2010),
as amended 78 FR 40542 (July 5, 2013);
• Prisoner Update Processing System
(PUPS), SSA/OPB, 60–0269, 64 FR
11076 (March 8, 1999), as amended 72
FR 69723 (December 10, 2007) and 78
FR 40542 (July 5, 2013);
• Master Beneficiary Record, SSA/
ORSIS, 60–0090, 71 FR 1826 (January
11, 2006), as amended 72 FR 69723
(December 10, 2007) and 78 FR 40542
(July 5, 2013);
• Earnings Recording and SelfEmployment Income System, SSA/
OEEAS, 60–0059, 71 FR 1819 (January
11, 2006), as amended 78 FR 40542 (July
5, 2013).
INCLUSIVE DATES OF THE MATCH:
The modifications to the CMP shall
become effective no sooner than 40 days
after the report of the modifications to
the matching program is sent to OMB
and Congress, or 30 days after
publication in the Federal Register,
whichever is later. The modifications to
the existing matching program will
continue for the duration of the
Agreement and may be extended for an
additional 12 months thereafter, if
certain conditions are met.
[FR Doc. 2014–13249 Filed 6–5–14; 8:45 am]
wreier-aviles on DSK5TPTVN1PROD with NOTICES
BILLING CODE 4120–03–P
Proposed Collection; 60-Day Comment
Request; State and Community
Tobacco Control Research Initiative
Evaluation (NCI)
In compliance with the
requirement of Section 3506(c)(2)(A) of
the Paperwork Reduction Act of 1995,
for opportunity for public comment on
proposed data collection projects, the
National Institutes of Health (NIH) will
publish periodic summaries of proposed
projects to be submitted to the Office of
Management and Budget (OMB) for
review and approval.
Written comments and/or suggestions
from the public and affected agencies
are invited to address one or more of the
following points: (1) Whether the
proposed collection of information is
necessary for the proper performance of
the function of the agency, including
whether the information will have
practical utility; (2) The accuracy of the
agency’s estimate of the burden of the
proposed collection of information,
including the validity of the
methodology and assumptions used; (3)
The quality, utility, and clarity of the
information to be collected; and (4)
Minimize the burden of the collection of
information on those who are to
respond, including the use of
appropriate automated, electronic,
mechanical, or other technological
collection techniques or other forms of
information technology.
To submit comments in writing,
request more information on the
proposed project, or to obtain a copy of
the data collection plans and
instruments, contact Elizabeth M.
Ginexi, Ph.D., Tobacco Control Research
Branch, Behavioral Research Program,
Division of Cancer Control and
Population Sciences, National Cancer
Institute, 9609 Medical Center Drive,
Room 3E564 MSC 9761, Bethesda,
Maryland 20892–9761 or call non-tollfree number 240–276–6765 or Email
your request, including your address to:
LGinexi@mail.nih.gov.
Comments regarding this information
collection are best assured of having
their full effect if received within 60
days of the date of this publication.
SUMMARY:
Proposed Collection: State and
Community Tobacco Control Research
Initiative Evaluation (SCTC), 0925, NEW
submission, National Cancer Institute
(NCI), National Institutes of Health
(NIH).
Need and Use of Information
Collection: The National Cancer
Institute State and Community Tobacco
Control Research Initiative is a program
within the Tobacco Control Research
Branch in the Behavioral Research
Program of the Division of Cancer
Control and Population Sciences. The
program targets 4 high-priority tobacco
control research areas at the state and
community level in the United States:
(1) Secondhand smoke policies, (2)
Tobacco tax and pricing policies, (3)
Mass media countermeasures and
community and social norms, and (4)
Tobacco industry practices. The
initiative supports innovative research
to yield rapid and actionable findings
for state and community tobacco control
programs. The purpose of the evaluation
is to assess the dissemination,
implementation, and community
collaboration processes of the grantees
and their respective state and
community partners and stakeholders.
The evaluation will utilize archival
grant project data and archival data
collected from the scientists in the first
two years of the initiative. The
evaluation also will collect new data to:
(1) Determine relationships,
interactions, and connectedness among
different network partnerships over time
and with policy makers; (2) assess the
utility of research tools, interventions,
products, and findings from the
perspective of key tobacco control
stakeholders; and (3) determine key
indicators for broad adoption of
research products. Results will address
research-to-practice gaps by providing a
critical window into the process of
disseminating evidence-based research
tools, products, and science findings in
community public health settings.
Intended audiences include staff at NIH
Institutes and Centers interested in
supporting translation/dissemination
and implementation science.
OMB approval is requested for one
year. There are no costs to respondents
other than their time. The total
estimated annualized burden hours are
112.
ESTIMATED ANNUALIZED BURDEN HOURS
Number of
respondents
Type of respondent
Data collection type
SCTC Scientist .................................
Affiliated Partner ..............................
Web Survey .....................................
Web Survey .....................................
VerDate Mar<15>2010
13:59 Jun 05, 2014
Jkt 232001
PO 00000
Frm 00052
Fmt 4703
Sfmt 4703
Number of
responses per
respondent
60
71
E:\FR\FM\06JNN1.SGM
Average burden
per response
(in hours)
1
1
06JNN1
20/60
20/60
Total annual
burden hours
20
24
32743
Federal Register / Vol. 79, No. 109 / Friday, June 6, 2014 / Notices
ESTIMATED ANNUALIZED BURDEN HOURS—Continued
Number of
respondents
Number of
responses per
respondent
Average burden
per response
(in hours)
Total annual
burden hours
Type of respondent
Data collection type
21
7
1
1
40/60
5/60
14
1
Pilot Project ......................................
Working Group .................................
Coordinating Center .........................
PI/Co-PI ............................................
Telephone Interview ........................
Script to Schedule Telephone Interview.
Telephone Interview ........................
Telephone Interview ........................
Telephone Interview ........................
Expert Panel ....................................
Consent Form ..................................
Telephone Script to Schedule Interview.
Telephone Interview ........................
6
6
2
18
18
6
1
1
1
1
1
1
40/60
40/60
40/60
1.5
5/60
5/60
4
4
1
27
2
1
21
1
40/60
14
..........................................................
........................
........................
Total ..........................................
Dated: June 2, 2014.
Karla Bailey,
NCI Project Clearance Liaison, NCI, NIH.
[FR Doc. 2014–13271 Filed 6–5–14; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
The inventions listed below
are owned by an agency of the U.S.
Government and are available for
licensing in the U.S. in accordance with
35 U.S.C. 209 and 37 CFR Part 404 to
achieve expeditious commercialization
of results of federally-funded research
and development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
SUMMARY:
wreier-aviles on DSK5TPTVN1PROD with NOTICES
FOR FURTHER INFORMATION CONTACT:
Licensing information and copies of the
U.S. patent applications listed below
may be obtained by writing to the
indicated licensing contact at the Office
of Technology Transfer, National
Institutes of Health, 6011 Executive
Boulevard, Suite 325, Rockville,
Maryland 20852–3804; telephone: 301–
496–7057; fax: 301–402–0220. A signed
Confidential Disclosure Agreement will
be required to receive copies of the
patent applications.
SUPPLEMENTARY INFORMATION:
Technology descriptions follow.
VerDate Mar<15>2010
13:59 Jun 05, 2014
Jkt 232001
RNA Splicing Inhibitors To Treat
Cancers
Description of Technology:
Vemurafenib is a B-Raf enzyme
inhibitor that causes cell death in
melanoma tumor cells that possess a
mutated B-Raf protein (V600E BRAF
mutation); however, patients rapidly
develop resistance. One mechanism for
acquired resistance of these patients to
BRAF inhibitors has been found to be
mediated by the existence of BRAF
(V600E) splicing variants that possess
structural changes in BRAF that confer
insensitivity to BRAF inhibitors.
Researchers at the National Cancer
Institute have discovered that RNA
splicing inhibitors can block the growth
of vemurafenib-resistant tumors.
Further, the researchers have also found
that other types of tumors that possess
BRAF splicing isoforms are susceptible
to RNA splicing inhibitors.
Available for licensing are methods of
using RNA splicing inhibitors to treat
tumors, including melanomas, and
methods to detect tumors that possess
certain BRAF splicing isoforms
susceptible to RNA splicing inhibitors.
Potential Commercial Applications:
Therapeutic agents to treat tumors.
Competitive Advantages: No
discernible toxicity in mice.
Development Stage: Early-stage; In
vitro data available; In vivo data
available (animal).
Inventors: Thomas A. Misteli and
Maayan Salton-Morgenstern (NCI).
Intellectual Property: HHS Reference
No. E–065–2014/0—U.S. Application
No. 61/974,378 filed 02 Apr 2014.
Licensing Contact: Patrick McCue,
Ph.D.; 301–435–5560; mccuepat@
od.nih.gov.
Collaborative Research Opportunity:
The National Cancer Institute is seeking
statements of capability or interest from
parties interested in collaborative
research to further develop, evaluate or
PO 00000
Frm 00053
Fmt 4703
Sfmt 4703
..........................
112
commercialize the development of RNA
splicing modulators as therapeutic
agents in cancer. For collaboration
opportunities, please contact John D.
Hewes, Ph.D. at hewesj@mail.nih.gov.
Treatment of Chronic Kidney Disease
With Synthetic Amphipathic Peptides
Description of Technology: The
invention is directed to treatment of
chronic kidney disease by administering
a synthetic, amphipathic helical peptide
known as 5A–37pA, and novel
derivatives thereof. Scientists at NIDDK
have demonstrated that invention
peptides antagonize activity of a
particular scavenger receptor known as
CD36. Using an in vivo model, NIDDK
scientists have shown that invention
peptides slowed progression of chronic
kidney disease and can potentially be
utilized as a therapeutic treatment.
Additionally, certain invention
peptides bind selectively to CD36 with
high specificity over other homologous
scavenger receptors. Thus, invention
peptides can be utilized as a research
tool to further evaluate the complex
etiology of chronic kidney disease.
5A–37pA, and derivatives thereof, are
peptide mimetic of apolipoprotein A–1.
These peptides have been described in
NIH owned patents and/or patent
applications (see, for example, U.S.
Patent Nos. 7,572,771 and 8,071,746 and
8,148,323). Use of these peptides, as
well as the novel peptides of this
invention, for the treatment of kidney
diseases is currently available for
licensing.
Potential Commercial Applications:
Therapeutic; Research Tool.
Competitive Advantages: Selective
antagonist of CD36 activity; Specific
binding to CD36 over other scavenger
receptors.
Development Stage: Early-stage; In
vitro data available; In vivo data
available (animal).
E:\FR\FM\06JNN1.SGM
06JNN1
Agencies
[Federal Register Volume 79, Number 109 (Friday, June 6, 2014)]
[Notices]
[Pages 32742-32743]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2014-13271]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Proposed Collection; 60-Day Comment Request; State and Community
Tobacco Control Research Initiative Evaluation (NCI)
SUMMARY: In compliance with the requirement of Section 3506(c)(2)(A) of
the Paperwork Reduction Act of 1995, for opportunity for public comment
on proposed data collection projects, the National Institutes of Health
(NIH) will publish periodic summaries of proposed projects to be
submitted to the Office of Management and Budget (OMB) for review and
approval.
Written comments and/or suggestions from the public and affected
agencies are invited to address one or more of the following points:
(1) Whether the proposed collection of information is necessary for the
proper performance of the function of the agency, including whether the
information will have practical utility; (2) The accuracy of the
agency's estimate of the burden of the proposed collection of
information, including the validity of the methodology and assumptions
used; (3) The quality, utility, and clarity of the information to be
collected; and (4) Minimize the burden of the collection of information
on those who are to respond, including the use of appropriate
automated, electronic, mechanical, or other technological collection
techniques or other forms of information technology.
To submit comments in writing, request more information on the
proposed project, or to obtain a copy of the data collection plans and
instruments, contact Elizabeth M. Ginexi, Ph.D., Tobacco Control
Research Branch, Behavioral Research Program, Division of Cancer
Control and Population Sciences, National Cancer Institute, 9609
Medical Center Drive, Room 3E564 MSC 9761, Bethesda, Maryland 20892-
9761 or call non-toll-free number 240-276-6765 or Email your request,
including your address to: LGinexi@mail.nih.gov.
Comments regarding this information collection are best assured of
having their full effect if received within 60 days of the date of this
publication.
Proposed Collection: State and Community Tobacco Control Research
Initiative Evaluation (SCTC), 0925, NEW submission, National Cancer
Institute (NCI), National Institutes of Health (NIH).
Need and Use of Information Collection: The National Cancer
Institute State and Community Tobacco Control Research Initiative is a
program within the Tobacco Control Research Branch in the Behavioral
Research Program of the Division of Cancer Control and Population
Sciences. The program targets 4 high-priority tobacco control research
areas at the state and community level in the United States: (1)
Secondhand smoke policies, (2) Tobacco tax and pricing policies, (3)
Mass media countermeasures and community and social norms, and (4)
Tobacco industry practices. The initiative supports innovative research
to yield rapid and actionable findings for state and community tobacco
control programs. The purpose of the evaluation is to assess the
dissemination, implementation, and community collaboration processes of
the grantees and their respective state and community partners and
stakeholders. The evaluation will utilize archival grant project data
and archival data collected from the scientists in the first two years
of the initiative. The evaluation also will collect new data to: (1)
Determine relationships, interactions, and connectedness among
different network partnerships over time and with policy makers; (2)
assess the utility of research tools, interventions, products, and
findings from the perspective of key tobacco control stakeholders; and
(3) determine key indicators for broad adoption of research products.
Results will address research-to-practice gaps by providing a critical
window into the process of disseminating evidence-based research tools,
products, and science findings in community public health settings.
Intended audiences include staff at NIH Institutes and Centers
interested in supporting translation/dissemination and implementation
science.
OMB approval is requested for one year. There are no costs to
respondents other than their time. The total estimated annualized
burden hours are 112.
Estimated Annualized Burden Hours
----------------------------------------------------------------------------------------------------------------
Number of Average burden
Type of respondent Data collection Number of responses per per response Total annual
type respondents respondent (in hours) burden hours
----------------------------------------------------------------------------------------------------------------
SCTC Scientist............... Web Survey...... 60 1 20/60 20
Affiliated Partner........... Web Survey...... 71 1 20/60 24
[[Page 32743]]
Telephone 21 1 40/60 14
Interview.
Script to 7 1 5/60 1
Schedule
Telephone
Interview.
Pilot Project................ Telephone 6 1 40/60 4
Interview.
Working Group................ Telephone 6 1 40/60 4
Interview.
Coordinating Center.......... Telephone 2 1 40/60 1
Interview.
PI/Co-PI..................... Expert Panel.... 18 1 1.5 27
Consent Form.... 18 1 5/60 2
Telephone Script 6 1 5/60 1
to Schedule
Interview.
Telephone 21 1 40/60 14
Interview.
----------------------------------------------------------------------------------
Total.................... ................ .............. .............. ............... 112
----------------------------------------------------------------------------------------------------------------
Dated: June 2, 2014.
Karla Bailey,
NCI Project Clearance Liaison, NCI, NIH.
[FR Doc. 2014-13271 Filed 6-5-14; 8:45 am]
BILLING CODE 4140-01-P